Market Runner: What Will Happen to vTv Therapeutics Inc Next? The Stock Just Increased A Lot
The stock of vTv Therapeutics Inc (NASDAQ:VTVT) is a huge mover today! About 77,150 shares traded hands or 31.77% up from the average. vTv Therapeutics Inc (NASDAQ:VTVT) has declined 4.95% since May 13, 2016 and is downtrending. It has underperformed by 15.48% the S&P500. The move comes after 5 months positive chart setup for the $176.11M company. It was reported on Dec, 16 by Barchart.com. We have $5.76 PT which if reached, will make NASDAQ:VTVT worth $14.09 million more.
Analysts await vTv Therapeutics Inc (NASDAQ:VTVT) to report earnings on March, 7. They expect $-0.20 earnings per share, up 42.86% or $0.15 from last yearâs $-0.35 per share. After $-0.41 actual earnings per share reported by vTv Therapeutics Inc for the previous quarter, Wall Street now forecasts -51.22% EPS growth.
vTv Therapeutics Inc (NASDAQ:VTVT) Ratings Coverage
Out of 3 analysts covering vTv Therapeutics Inc (NASDAQ:VTVT), 3 rate it a âBuyâ, 0 âSellâ, while 0 âHoldâ. This means 100% are positive. vTv Therapeutics Inc has been the topic of 3 analyst reports since August 24, 2015 according to StockzIntelligence Inc. Canaccord Genuity initiated vTv Therapeutics Inc (NASDAQ:VTVT) rating on Friday, September 4. Canaccord Genuity has âBuyâ rating and $15 price target. The company was initiated on Monday, August 24 by Stifel Nicolaus. The firm earned âOverweightâ rating on Monday, August 24 by Piper Jaffray.
According to Zacks Investment Research, âvTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase kmspico  activator download  TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Companyâs drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.â
More recent vTv Therapeutics Inc (NASDAQ:VTVT) news were published by: Bizjournals.com which released: âTriad firm reports positive results for study of diabetes treatmentâ on December 16, 2016. Also Businesswire.com published the news titled: âvTv Therapeutics to Participate in Upcoming Mizuho, Stifel and Piper Jaffray âŠâ on November 10, 2016. Businesswire.comâs news article titled: âvTv Therapeutics Reports Third Quarter Financial and Operational Results and âŠâ with publication date: November 02, 2016 was also an interesting one.
VTVT Company Profile
vTv Therapeutics Inc., incorporated on April 02, 2015, is a clinical-stage biopharmaceutical company. The Firm is engaged in the discovery and development of orally administered small molecule drug candidates. The Companyâs drug candidate for the treatment of Alzheimerâs disease (AD), azeliragon (TTP488), is an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial (the STEADFAST Study) under a Food and Drug Administration (FDA) agreed Special Protocol Assessment (SPA). The Companyâs type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial (the AGATA Study), and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
vTv Therapeutics Inc-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
via source:https://friscofastball.com/2016/12/16/market-runner-what-will-happen-to-vtv-therapeutics-inc-next-the-stock-just-increased-a-lot/















